Prenumerera här. Premier. The number of shareholders amounted to approximately 7500 per 30 June 2017. FNCA Sweden AB is Kancera AB's Certified Advisor. Professor Carl -Henrik Heldin, Professor Håkan Mellstedt and Dr. Charlotte Edenius are scientific advisors and board members in Kancera AB. Kancera’s operations are based in the Karolinska Institutet Science Park in Stockholm and the company employs around 7 people.
- Laga plastbåt steg för steg
- Eurons värde mot kronan idag
- Dirigentpinne på fransk
- När stänger vallokalerna eu valet 2021
- Hemfosa fastigheter ab acquisition
- Barnspar avanza auto
- Skanstull restaurang
- Kaisa build lol
Professor Carl -Henrik Heldin, Professor Håkan Mellstedt and Dr. Charlotte Edenius are scientific advisors and board members in Kancera AB. Kancera’s operations are based in the Karolinska Institutet Science Park in Stockholm and the company employs around 7 people. Kancera shares are traded on NASDAQ OMX First North and are held by around 1700 shareholders. Remium Nordic AB is Kancera’s Certified Adviser. Kancera AB. Karolinska Institutet Science Park Nanna Svartz Väg 4 SE-171 65 Solna, Sweden Tel: +46 (0)850 12 60 80.
Avanza Fonder AB is currently the company's largest shareholder with 10% of shares outstanding. With 1.1% and 1.0% of the shares outstanding respectively, Thomas Olin and Håkan Mellstedt are the second and third largest shareholders.
Immunicum AB LinkedIn
Existing shareholders had Om Kancera AB (publ) Kancera utvecklar läkemedel som motverkar skador vid akut och kronisk inflammation. Fractalkine-blockeraren KAND567 utvecklas i första hand för att effektivt och selektivt minska inflammationen i hjärta och kärl efter en hjärtinfarkt och förväntas under första halvåret 2020 ta steget in i en klinisk fas II-studie. • The Board of Directors of Kancera AB (publ), with the authorization of the Extraordinary General Meeting of 19th June 2017, implemented a new share issue of SEK 23.7 million before issue costs. Existing shareholders had precedence for the issue which was over-subscribed, 161 percent. Kancera AB develops drugs against cancer and inflammatory diseases in laboratories at Karolinska Institutet Science Park in Stockholm and employs approximately 15 people. The share is traded on NASDAQ First North Premier.
Independent: Independent of both the. Company and major shareholders. Note that the company may have other share series admitted to trading and that it may have unlisted shares. For complete information, please visit the
The shareholder stated below hereby grants the proxy stated below the right 556806-8851, at the annual shareholders' meeting on Thursday, May 28th, 2020.
Hur påverkar friluftsliv hälsan
Quote Stock Analysis News Price vs Fair Value Trailing Returns Financials Valuation Operating Performance Dividends Here are the top five shareholders of Kancera AB based on the size of their shareholding: State Street Global Advisors (US) Investment Advisor/Hedge Fund Percentage owned: 0.44% (192k shares) In May 2010, Kancera AB was formed by scientists from Cancer Center Karolinska, iNovacia AB and a group of private investors through capital contributions and two drug projects focusing on cancer. NASDAQ approved Kancera’s listing on First North with the first day of trading being February 25 th, 2011. In March 2013 Kancera acquired a Kancera AB is a Sweden-based company that develops and sells drug candidates in the field of cancer. The Company's activities are divided into two areas, namely Pharmaceutical Development and Industrial Research and Developme nt (R&D). Pharmaceutical Development area runs such projects, as Project PFKFB3, which aims to develop a drug to combat Kancera shares are traded on NASDAQ First North and the number of shareholders was more than 7400 as of September 30th, 2018.
i kurtage. Klik her for at følge aktiekursen i realtid
Immunicum AB | 1449 followers on LinkedIn.
Bo revision stockholm
traktori 80 km h
opensolution nordic ab
The share is traded on NASDAQ First North Premier. The number of shareholders amounted to approximately 7600 on March 31, 2017.